RxDoctor Payments Data

Nathaniel Schuster, MD

Pain Medicine · San Diego, CANPI 1861781205

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Lilly USA, LLC at 36.6% of the total. Reporting peaked in 2023 at $96,860 and has fallen 73.4% since, to $25,808 in 2025. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$336,582in general payments, 2019–2025

Across 511 payments — averaging $658.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$123K
  • Averitas Pharma Inc.$63K
  • GRT US Holding, Inc.$59K
  • Collegium Pharmaceutical, Inc.$58K
  • Vertex$17K
  • H. Lundbeck A S$6K
  • plus $10K from 20 others
$29,821in research payments, 2019–2025

Across 2 payments — averaging $14,910 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endo Pharmaceuticals Inc.$15K
  • Purdue Pharma L.p.$15K

What the payments were for

  • Consulting fees$90,64227%
  • Speaking & faculty fees$184,64055%
  • Grants$850%
  • Travel & lodging$52,24616%
  • Food & beverage$8,9623%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$336,582 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$97,762
Medicare patients
266
Services billed
1,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm27$20,175
Emgality SyringeGalcanezumab-Gnlm11$16,839
RizatriptanRizatriptan Benzoate13$137

Paid to pharmacies, not to this prescriber.

Other pain medicine in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →